Table 1.
Sampling fraction versus transmission cluster (5 SNPs cut-off, same MDR-resistance SNPs).
| Year | WHO RR-TB notification, corrected* | Included in analysis (%) | unclustered isolates n (%) | Isolates in cluster n (%) | Isolates in the R3clone n (%) |
|---|---|---|---|---|---|
| 1991–2005 | – | 96 | 21 (21·9) | 75 (78·1) | 59 (61·5) |
| 2006–2013 | 479 | 93 (19·4) | 5 (5·4) | 88 (94·6) | 78 (83·9) |
| 2014 | 73 | 12 (16·4) | 4 (33·3) | 8 (66·7) | 6 (50·0) |
| 2015 | 88 | 31 (35·2) | 6 (19·3) | 25 (80·7) | 19 (61·3) |
| 2016 | 69 | 26 (37·7) | 4 (15·4) | 22 (84·6) | 22 (84·6) |
| 2017/2018# | 58 | 50 (86·2%) | 9 (18·0) | 41 (82·0) | 29 (59·2) |
| Total¥ | 767 | 212 (27.6) | 28 (13.2) | 184 (86.8) | 154 (72.6) |
*Based on a recent finding, only 14·3% of RR on Xpert with a very low bacterial load was confirmed as rifampicin-resistant (RR); #including Jan-March (2018/03) with only 9 confirmed RR patients being registered in this period; ¥Exclude 96 isolates collected between 1991 and 2005 as no notification data for that period. MDR = multidrug resistant; SNPs = single nucleotide polymorphisms.